Zylox-Tonbridge Medical Technology Co., Ltd.
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices China and internationally. It primarily offers ThromBite Clot Retriever Device, which is intended to restore bl…
Medical - Devices
CN, Hangzhou [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -95.88 | -108.97 | -55.63 | |
| Graham Fair Price | 0.00 | 3.71 | 3.71 | |
| PEG | inf | 0.00 | -1.24 | |
| Price/Book | 54.28 | 1.21 | 0.79 | |
| Price/Cash Flow | 54.28 | 182.25 | 118.13 | |
| Prices/Earnings | -54.28 | -42.74 | -27.70 | |
| Price/Sales | 54.28 | 24.83 | 16.09 | |
| Price/FCF | 54.28 | 182.25 | 118.13 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 0.00 | 0.72 | 0.72 | |
| Operating Margin | 0.00 | -0.22 | -0.22 | |
| ROA | 0.00 | < 0.005 | < 0.005 | |
| ROE | < 0.005 | < 0.005 | 0.00 | |
| ROIC | -0.01 | -0.01 | 0.13 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.08 | 1.66 | -95.32 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.21 | 0.00 | inf | |
| EPS QOQ | -0.22 | 0.00 | inf | |
| FCF QOQ | 1.30 | 0.00 | inf | |
| Revenue QOQ | 0.29 | 0.00 | inf | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Positive
Fundamentals
Leverage & Liquidity
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 396.99 | 359.96 | -9.33 | |
| Days Sales Outstanding (DSO) | 0.71 | 0.71 | 0.00 | |
| Inventory Turnover | 0.23 | 0.25 | 10.29 | |
| Debt/Capitalization | 0.02 | 0.02 | 7.61 | |
| Quick Ratio | 4.54 | 4.76 | 4.76 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 9.30 | 9.30 | 0.00 | |
| Cash | 4.40 | 4.61 | 4.77 | |
| Capex | -0.12 | -0.12 | 0.00 | |
| Free Cash Flow | 0.06 | 0.06 | 0.00 | |
| Revenue | 0.45 | 0.45 | 0.00 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad